EANS-News: Sangui Bio Tech International Inc. / Over 500 Customers: Granulox Sales Ahead of Planning

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Sales Progress

Subtitle: Initial investments will have amortized by 2014 according
to SastoMed / Licensing agreement will yield income for Sangui with
the beginning of 2013, exponential growth expected

Witten, Germany, August 13, 2012 (euro adhoc) - SastoMed GmbH, global
licensee of the Sangui patented wound spray, has submitted the
announced report covering the first 100 days of Granulox product
sales. The report is available on www.sastomed.de. Its results meet
and in some parts considerably exceed the expectations which were
directed at the joint venture company by SanguiBioTech GmbH as the
licenser. SastoMed assumes that the initial investments will have
amortized by 2014. Before that already, Sangui will participate in
each Euro of revenue in Germany and abroad and will profit by the
considerable growth dynamic. The sales strategy is based on an
exemplary assessment of the complex health market the accuracy of
which is underpinned by the presented sales progress. Until July 31,
the sales force had arranged for almost 4,800 meetings and handed
over more than 1,000 samples. After no more than 100 days about 500
customers have been registered as actively purchasing the product.
With this customer base SastoMed are ahead of planning. In addition,
the sales team is present at most conferences, trade shows or
workshops dedicated to wound management. The communication with
opinion leaders and the expert public will now be complemented by an
extensive advertising campaign in the consumer media and the
internet. Still, personal contact and practical experience are
decisive to convince the users. As had been expected according to the
findings of Sangui research and development, impressive documentation
of successful wound treatments underline the excellent efficacy of
Granulox in everyday health care practice. For some time it had been
known among medical researchers that there is a correlation between
hypoxia and impeded wound healing. Thanks to its research focus on
oxygen Sangui was the first and only company to draw the right
conclusions and to develop a hemoglobin based technology which
actually and effectively enhances the oxygen supply and thus supports
wound therapies. The growing dynamics in penetrating the market will
even increase further next year according to SastoMed: Overall
another 5,000 doctors and 500 hospitals are planned to be gained to
regularly administer Granulox in Germany alone. At the same time
internationalizing the business will move up on the agenda. The
current positive experiences made in Germany will among others also
lead to entrusting the leadership in operating sales in Mexico to
SastoMed - for the sake of a consistent market appearance and in
accordance with the Mexican partners. In parallel, market entry in
Austria, the United Kingdom and Turkey are under preparation.
Additional European markets are planned to be addressed in 2014. The
international business will be directed by a top marketing and sales
manager with international track record. More details will be
disclosed after the signing of the final articles of employment.
Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, was
impressed by these preliminary statements: "We at Sangui are
particularly proud of the fact that our yearlong focus on this
technology was the right move. We are especially glad to obtain such
a positive response from competent experts, who confirm our great
expectations. And we are delighted to see how many patients now
experience the benefits of Granulox treatment. Our strategic decision
to transfer marketing and sales of the Sangui developed technology to
highly professional partners has proven to be the best possible
choice. We support this intense growth course also on the financial
side and intend to push-start the international activities. We can
foresee that beginning end of this year but increasingly so over the
years to come the positive cash flow from the joint venture company
will more than justify our decisions."

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (179) 7963472
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English